Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Bone Marrow Transplant. 2016 Aug 22;52(2):173–182. doi: 10.1038/bmt.2016.203

Table 5. Risk factors to consider when screening for components of metabolic syndrome in transplant recipients.

  • Personal history

  • Family history

  • Type of transplant (allogeneic or autologous)

  • TBI as part of pre-transplant conditioning

  • Development of acute or chronic GVHD

  • Ongoing therapy with corticosteroids

  • Ongoing therapy with calciunerin inhibitors

  • Ongoing therapy with sirolimus

  • Presence of additional metabolic syndrome components